Related Experiment Videos

Imipenem resistance in nonfermenters causing nosocomial urinary tract infections

N Taneja1, S Maharwal, M Sharma

  • 1Department of Medical Microbiology, PGIMER, Chandigarh-160012, India.

Insights

Nonfermenting gram-negative bacilli are opportunistic pathogens resistant to common antibiotics. Imipenem resistance was observed in 36.4% of these nosocomial pathogens, impacting treatment options.

Area of Science:

  • Clinical Microbiology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Nonfermenting gram-negative bacilli (nonfermenters) are significant nosocomial pathogens.
  • These bacteria frequently cause opportunistic infections in immunocompromised individuals.
  • Nonfermenters exhibit high resistance to common antibiotic classes like beta-lactams, fluoroquinolones, and aminoglycosides.

Purpose of the Study:

  • To evaluate the in vitro susceptibility of nosocomial nonfermenters to imipenem.
  • To compare antimicrobial resistance patterns between imipenem-susceptible and imipenem-resistant nonfermenter strains.

Main Methods:

  • Eighty-five nonfermenter isolates from nosocomial urinary tract infections were analyzed.
  • Minimum Inhibitory Concentration (MIC) of imipenem was determined using the agar dilution method.
  • Antibiotic susceptibility profiles were compared between imipenem-sensitive and resistant groups.

Main Results:

  • Overall, 36.4% of nonfermenters demonstrated resistance to imipenem.
  • Imipenem resistance rates were 42% for Pseudomonas aeruginosa and 18.5% for Acinetobacter baumanii.
  • High resistance (>70%) was noted for ceftazidime, gentamicin, and ciprofloxacin, while piperacillin and amikacin showed better susceptibility.
  • No significant differences in antibiotic susceptibility were observed between imipenem-sensitive and imipenem-resistant strains.

Conclusions:

  • A substantial proportion of nosocomial nonfermenters are resistant to imipenem, a key carbapenem antibiotic.
  • Understanding resistance patterns is crucial for effective management of infections caused by these challenging pathogens.
  • Piperacillin and amikacin appear to be more reliable options based on in vitro susceptibility, though further clinical correlation is needed.

Related Concept Videos